This is a working overview of lipolysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-14 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Some Māori tribes from New Zealand would keep mummified heads as trophies from tribal warfare. They are also known as Mokomokai. In the 19th century, many of the trophies were acquired by Europeans who found the tattooed skin to be a phenomenal curiosity. Westerners began to offer valuable commodities in exchange for the uniquely tattooed mummified heads. The heads were later put on display in museums, 16 of them in France alone. In 2010, at a ceremony in the Hôtel de Ville in Rouen, Rouen City Council returned one of the heads to New Zealand, despite earlier protests by the Culture Ministry of France. There is also evidence that some Māori tribes may have practiced full-body mummification, though the practice is not thought to have been widespread. The discussion of Māori mummification has been historically controversial, with some experts in past decades claiming that such mummies have never existed. The historical significance of full-body mummification within Māori culture is acknowledged by science, although there is still debate as to the nature of their exact mummification processes. Some mummies appear to have been spontaneously created by the natural environment, while others exhibit signs of direct human involvement. Generally, modern consensus tends to agree that there could have been a mixture of both types of mummification, similar to that of the Ancient Egyptian culture.
Gavin Christopher Newsom (born October 10, 1967) is an American politician and businessman serving since 2019 as the 40th governor of California. A member of the Democratic Party, he served from 2011 to 2019 as the 49th lieutenant governor of California and from 2004 to 2011 as the 42nd mayor of San Francisco. Born and raised in San Francisco, Newsom graduated from Santa Clara University in 1989 with a Bachelor of Science in political science. Afterward, he founded the boutique winery PlumpJack Group in Oakville, California, with billionaire heir and family friend Gordon Getty as an investor. The company grew to manage 23 businesses, including wineries, restaurants, and hotels. Newsom began his political career in 1996, when San Francisco mayor Willie Brown appointed him to the city's Parking and Traffic Commission. Brown then appointed Newsom to fill a vacancy on the Board of Supervisors the next year and Newsom was first elected to the board in 1998. Newsom was elected mayor of San Francisco in 2003 and reelected in 2007. He was elected lieutenant governor of California in 2010 and reelected in 2014. As lieutenant governor, Newsom hosted The Gavin Newsom Show from 2012 to 2013 and in 2013 wrote the book Citizenville, which focuses on using digital tools for democratic change. Newsom was elected governor in 2018 and reelected in 2022. He faced criticism for his personal behavior and leadership style during the COVID-19 pandemic, which contributed to an unsuccessful recall effort in 2021.
== Biological function == Ubiquinol-cytochrome-c reductase (also known as bc1 complex or complex III) is an enzyme complex of bacterial and mitochondrial oxidative phosphorylation systems. It catalyses the oxidation-reduction reaction of the mobile components ubiquinol and cytochrome c, contributing to an electrochemical potential difference across the mitochondrial inner or bacterial membrane, which is linked to ATP synthesis. The complex consists of three subunits in most bacteria, and nine in mitochondria: both bacterial and mitochondrial complexes contain cytochrome b and cytochrome c1 subunits, and an iron–sulfur 'Rieske' subunit, which contains a high potential 2Fe-2S cluster. The mitochondrial form also includes six other subunits that do not possess redox centres. Plastoquinone-plastocyanin reductase (b6f complex), present in cyanobacteria and the chloroplasts of plants, catalyses the oxidoreduction of plastoquinol and cytochrome f. This complex, which is functionally similar to ubiquinol-cytochrome c reductase, comprises cytochrome b6, cytochrome f and Rieske subunits. The Rieske subunit acts by binding either a ubiquinol or plastoquinol anion, transferring an electron to the 2Fe-2S cluster, then releasing the electron to the cytochrome c or cytochrome f heme iron. The reduction of the Rieske center increases the affinity of the subunit by several orders of magnitude, stabilizing the semiquinone radical at the Q(P) site. The Rieske domain has a [2Fe-2S] center.
== Community engagement and education == Breakthrough T1D offers education and resources, in both English and Spanish, for people of all living with T1D. Some of those who receive support are parents who care for children with T1D, children attending school with T1D, pregnant women with T1D, college students with T1D, and adults with T1D. Whether it is caring for children with T1D, sending children back to school safely, pregnancy and T1D, living with T1D as an adult, college life and T1D, and support groups. Breakthrough T1D also arranges community engagement which allows newly diagnosed families to connect with other T1D families for mutual support.
Sources: en.wikipedia.org
Carrey reunited with Joel Schumacher, director of Batman Forever, for The Number 23 (2007), a psychological thriller co-starring Virginia Madsen and Danny Huston. In the film, Carrey plays a man who becomes obsessed with the number 23, after finding a book about a man with the same obsession. The film was panned by critics. The following year Carrey provided his voice for Dr. Seuss' Horton Hears a Who! (2008). Carrey voiced Horton the Elephant for the CGI-animated feature, which was a box office success, grossing over $290 million worldwide. Carrey returned to live-action comedy, starring opposite Zooey Deschanel and Bradley Cooper in Yes Man (also 2008). Carrey played a man who signs up for a self-help program that teaches him to say yes to everything. Despite reviews being mixed, Rene Rodriquez of The Miami Herald stated, "Yes Man is fine as far as Jim Carrey comedies go, but it's even better as a love story that just happens to make you laugh." The film earned $225 million at the box office worldwide.
Adult cod are active hunters, feeding on sand eels, whiting, haddock, small cod, squid, crabs, lobsters, mussels, worms, mackerel, and molluscs. In the Baltic Sea the most important prey species are herring and sprat. Many studies that analyze the stomach contents of these fish indicate that cod is the top predator, preying on the herring and sprat. Sprat form particularly high concentrations in the Bornholm Basin in the southern Baltic Sea. Although cod feed primarily on adult sprat, sprat tend to prey on the cod eggs and larvae. Cod and related species are plagued by parasites. For example, the cod worm, Lernaeocera branchialis, starts life as a copepod-like larva, a small free-swimming crustacean. The first host used by the larva is a flatfish or lumpsucker, which it captures with grasping hooks at the front of its body. It penetrates the fish with a thin filament, which it uses to suck the fish's blood. The nourished larvae then mate on the fish. The female larva, with her now fertilized eggs, then finds a cod, or a cod-like fish such as a haddock or whiting. There the larva clings to the gills while it metamorphoses into a plump sinusoidal wormlike body with a coiled mass of egg strings at the rear. The front part of the worm's body penetrates the body of the cod until it enters the rear bulb of the host's heart. There, firmly rooted in the cod's circulatory system, the front part of the parasite develops like the branches of a tree, reaching into the main artery.
== Clinical significance == It was hoped that ANGPTL8 or its homolog in humans may provide an effective treatment for type 2 diabetes and perhaps even type I diabetes. Unfortunately, since new data have greatly called into question the ability of ANGPTL8 to increase beta-cell replication, its potential use as a therapy for type 2 diabetes is limited. Inhibition of ANGPTL8 represents a possible therapeutic strategy for hypertriglyceridemia. In a clinical trial, a human ANGPTL3/8 monoclonal antibody reduced the concentration of triglycerides (-70%), and low-density lipoprotein cholesterol (-32%), while increasing HDL- cholesterol (+27%), representing a promising therapy for multiple lipid disorders.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.